Dr. Sanjay Gupta

Hey there, welcome to Chasing Life.

You know, when Ozempic first hit the market in 2017, it was the start of a revolution.

The medication approved to treat type 2 diabetes was also helping people lose weight.

Sometimes a lot of it.

And that fact did not go unnoticed.

The drug seemed to usher in a paradigm shift in the field of weight management.

Other GLP receptor agonists, as they are called, soon followed.

Magovi, Manjaro, Zepbound.

They helped millions of people do what they had been unable to do before, lose weight, seemingly without effort.

So demand for them surged, no surprise.

And since they're widespread use, so has our understanding of them.

The landscape has changed a lot since we first reported on these drugs on Chasing Life.

So today we're bringing back my friend and colleague Meg Terrell, who has been covering them since the start.

She's going to update us on what is new, what's on the horizon.

And let me tell you, there's a lot to talk about.

I'm CNN Chief Medical Correspondent Dr. Sanjay Gupta, and this is Chasing Life.

Welcome back to Chasing Life.

Thank you for having me.

My favorite guest.

You and I, we know each other so well.